Nanomedicine & Targeted Delivery
Research |
Polymeric Nanoparticles as Therapeutic Platforms
The nanotechnology as a basic and applied science has uncovered a universe of creative possibilities, impacting almost all aspect of society. Our research attempts to generate advanced therapeutic strategies based on polymeric nanoparticles for the precise delivery of drugs. Since early stages of the preclinical drug development, including the fundamental understanding and interactions of nanoparticles and the life sciences, our group is also focused on the study of pharmacological and toxicological effects of nanoparticles in the physiological and/or pathological conditions. The innovative structure and composition of our nanotherapeutics formulations include the use of novel biomaterials and targeting molecules that support its smart performance and precise organ/tissue delivery.
Drug Delivery based on Microparticles Technology
The use of polymeric microparticles as controlled release technology provide a broad spectrum of therapeutic applications leading to the sustained release of drugs over long periods of time.
Our goal in this field is to develop innovative microtechnology systems based on novel biodegradable and biocompatible polymers suitable for the encapsulation and controlled release of antibiotics, chemotherapeutics and others molecules via intramuscular, oral and pulmonary delivery.
Novel Biomaterials for Nanotherapeutics
Polymer science is the key of current and future endeavor of drug delivery systems. Several parameter such as loading capacity, stability and the drug release mechanisms depend on the polymeric matrix of formulations. Our aim in this field is
to develop novel biocompatible materials for the advancement of field of nanotherapeutics.


Funding |
Current Research Support
-
Principal Investigator, Fondecyt Regular N° 1201147 (2020-2023).
-
Co-Investigator, Fondecyt Regular N° 1181408 (2018-2020).
-
Main Research of Basal Grant Nº AFB180001, CEDENNA (Nanobiomedicine, L6), CONICYT (2020 - 2023, III Phase).
-
Co-Investigator Nucleus-UNAB 2018 (2018-2020).
-
Research Associate of European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowsks-Curie Grant Agreement Nº 734801 (2017 - 2021).
-
Co-Sponsor of Postdoctoral FONDECYT Funding Nº 3180250 (2018 - 20120).




National |
Collaborators
Dora Altbir, Ph.D.
Center for Development of Nanoscience and Nanotechnology
Faculty of Science
University of Santiago
Santiago – Chile
Carmen Gloria Feijoo, Ph.D.
Laboratory of Immunology in fishes
Faculty of Life Sciences
Universidad Andres Bello
Santiago – Chile
Flavia Zacconi, Ph.D.
Laboratory of Design and Organic Synthesis
Faculty of Chemistry
Pontifical Catholic University of Chile
Santiago, Chile
Claudio Cabello/Verrugio, Ph.D.
Laboratory of Muscle Pathology, Fragility and Aging
Faculty of Life Sciences
Universidad Andres Bello
Santiago – Chile
Iván Palomo, Ph.D.
Faculty of Health Sciences
University of Talca
Talca – Chile
International |
Collaborators
Omid Farokhzad, MD.
Center for Nanomedicine – Farokhzad Lab
Brigham and Women's Hospital – Harvard Medical School.
Boston, USA
Jinjun Shi, Ph.D.
Brigham and Women's Hospital – Harvard Medical School.
Boston, USA
Won IL Choi, Ph.D.
Center for Convergence Bioceramic Materials, Convergence R&D Division
Korea Institute of Ceramic Engineering and Technology (KICET)
Seoul, Korea
Nazila Kamaly, Ph.D.
Molecular Science Research Hub
Imperial College London
London, UK
Basit Yameen Ph.D.
Department Of Chemistry & Chemical Engineering
LUMS University
Lahore, Pakistan
Carolina Salvador-Morales, Ph.D.
Laboratory of Nanotechnology and Nanomedicine
George Mason University
Fairfax, VA, USA



Proudly collaborating with
